Authorized purpose: Assist qualified medical professionals in assessing and evaluating cardiac function from multi-phase, multi-slice cardiovascular CT angiography images.
Clinical role
Post-processing cardiac-function analysis with editable LV cavity, LV myocardium, and RV cavity surfaces; users review and correct automated results or perform segmentation manually before measurement.
Images and patients
CT/CTA · Heart and cardiovascular structures
Key limitation
Keep in mind: The application is an aid to the existing standard of care and does not replace existing physician software. All generated surfaces are editable and users are advised to verify and correct errors; manual segmentation is available. The packet does not establish use outside the specified multi-phase cardiovascular CTA input or autonomous clinical decision-making.
Clinical detailsPurpose, workflow fit, evidence, and safety record
Workflow navigation pilot
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
What does this software do?Authorized purpose: Assist qualified medical professionals in assessing and evaluating cardiac function from multi-phase, multi-slice cardiovascular CT angiography images.
Which images or clinical context are in scope?Modality: CT/CTA Anatomy or clinical context: Heart and cardiovascular structures Input: Multi-phase, multi-slice cardiovascular CT angiography images in DICOM Standard format; the comparison table describes vendor-independent cardiac CTA input.
Who uses it?Intended users: Qualified medical professionals, including physicians, cardiologists, and radiologists
What does the software produce?Output: Manual or semi-automatic segmentation of LV cavity, LV myocardium, and RV cavity, with EDV, ESV, SV, EF, CO, CI, EDM, ESM, and EDESM displayed on screen and in a CT Function Report; MPR and 3D views are also described.
What is its most important limitation?Key limitation: The application is an aid to the existing standard of care and does not replace existing physician software. All generated surfaces are editable and users are advised to verify and correct errors; manual segmentation is available. The packet does not establish use outside the specified multi-phase cardiovascular CTA input or autonomous clinical decision-making.
Clinical takeaway. Clinical role: Assist qualified medical professionals in assessing and evaluating cardiac function from multi-phase, multi-slice cardiovascular CT angiography images.
Evidence takeaway. Evidence from the reviewed source record: FDA K241038 states that no clinical studies were necessary for substantial equivalence. ML validation used data from 9 sites, with 90% sampled from US sources and validation data separated from development data; reference standards used three expert readers. Reported segmentation endpoints were LV cavity MAE <10%, Dice >86%, Hausdorff distance <9.5 mm, and EF bias 1.3% (95% CI -12 to 14); RV cavity MAE <18%, Dice >85%, Hausdorff distance <18 mm, and EF bias -5.5% (95% CI -15 to 4.4); LV myocardium MAE <17%, Dice >82%, and Hausdorff distance <15 mm.
Evidence context
Evidence context not reviewed for this FDA record.
Public-label constraints
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Purpose
Assist qualified medical professionals in assessing and evaluating cardiac function from multi-phase, multi-slice cardiovascular CT angiography images.
Post-processing cardiac-function analysis with editable LV cavity, LV myocardium, and RV cavity surfaces; users review and correct automated results or perform segmentation manually before measurement.
Manual or semi-automatic segmentation of LV cavity, LV myocardium, and RV cavity, with EDV, ESV, SV, EF, CO, CI, EDM, ESM, and EDESM displayed on screen and in a CT Function Report; MPR and 3D views are also described.
The application is an aid to the existing standard of care and does not replace existing physician software. All generated surfaces are editable and users are advised to verify and correct errors; manual segmentation is available. The packet does not establish use outside the specified multi-phase cardiovascular CTA input or autonomous clinical decision-making.
FDA K241038 states that no clinical studies were necessary for substantial equivalence. ML validation used data from 9 sites, with 90% sampled from US sources and validation data separated from development data; reference standards used three expert readers. Reported segmentation endpoints were LV cavity MAE <10%, Dice >86%, Hausdorff distance <9.5 mm, and EF bias 1.3% (95% CI -12 to 14); RV cavity MAE <18%, Dice >85%, Hausdorff distance <18 mm, and EF bias -5.5% (95% CI -15 to 4.4); LV myocardium MAE <17%, Dice >82%, and Hausdorff distance <15 mm.
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Evidence summary
FDA K241038 states that no clinical studies were necessary for substantial equivalence. ML validation used data from 9 sites, with 90% sampled from US sources and validation data separated from development data; reference standards used three expert readers. Reported segmentation endpoints were LV cavity MAE <10%, Dice >86%, Hausdorff distance <9.5 mm, and EF bias 1.3% (95% CI -12 to 14); RV cavity MAE <18%, Dice >85%, Hausdorff distance <18 mm, and EF bias -5.5% (95% CI -15 to 4.4); LV myocardium MAE <17%, Dice >82%, and Hausdorff distance <15 mm.
No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.
Cardiac CT Function Software Application regulatory performance study summary
DesignStand-Alone Performance
PopulationPopulation described in the exact-submission ACR model card
Scopeexact submission
Tested versionExact product version not reported; regulatory study summarized for FDA submission K241038
Sites9
IndependenceIndependence not established
K241038
ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Postmarket safety review
The exact-identifier FDA recall query returned no native recall record for K241038. This limited result does not establish absence of recalls or other safety information and does not cover later versions, family records, MAUDE reports, corrections, or field notices.
IT implementationDeployment, interfaces, data handling, and support
System and version relationships
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Acquisition/source
Source context, not route validation: Multi-phase, multi-slice cardiovascular CT angiography images in DICOM Standard format; the comparison table describes vendor-independent cardiac CTA input.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Source context, not route validation: DICOM Standard input, on-screen results, and saved results for future review are established. The packet states that the module does not interface directly with data-collection equipment and that functionality depends on the acquisition vendor; a specific PACS, RIS, EHR, or deployment configuration is not established.
Scope: Exact FDA submission.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Unresolved route: Not established for the exact route.
Scope: Exact FDA submission. The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-08 ·
Returned objects
Source context, not route validation: Manual or semi-automatic segmentation of LV cavity, LV myocardium, and RV cavity, with EDV, ESV, SV, EF, CO, CI, EDM, ESM, and EDESM displayed on screen and in a CT Function Report; MPR and 3D views are also described.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Unresolved route: Manual or semi-automatic segmentation of LV cavity, LV myocardium, and RV cavity, with EDV, ESV, SV, EF, CO, CI, EDM, ESM, and EDESM displayed on screen and in a CT Function Report; MPR and 3D views are also described.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
Planned local route tests
No tests below have been performed or accepted.
Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.
Local implementation checklist
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
DICOM Standard input, on-screen results, and saved results for future review are established. The packet states that the module does not interface directly with data-collection equipment and that functionality depends on the acquisition vendor; a specific PACS, RIS, EHR, or deployment configuration is not established.
ACR AI Central provides an exact-submission model card for Cardiac CT Function Software Application; FDA labeling remains controlling for clinical use, limitations, and performance.
Sources & review detailsFDA identity, research record, source ledger, and history
Regulatory identity
FDA record and catalog context
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
This audit distinguishes completed source review from fields that have not yet been researched.
Exact FDA record reviewedStatus
2026-09-20Last searched
20Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads
The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, acr ai central product, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall
Field review details
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
Public pricing: Not verified - checked 2026-09-08 - Exact FDA submission
No public price or quote for the exact K241038 configuration was established in this review.
Pricing model: Not yet reviewed
Setup and integration fees: Not yet reviewed
Recurring fees: Not yet reviewed
Minimum commitment: Not yet reviewed
Contract duration: Not yet reviewed
Renewal terms: Not yet reviewed
Cancellation terms: Not yet reviewed
Support and service terms: Not yet reviewed
Trial or pilot terms: Not yet reviewed
Reimbursement: Not publicly available - checked 2026-09-08 - Exact FDA submission
No exact-product payer policy, coding instruction, or payment determination was established; eligibility must be evaluated by payer, site of service, and use case.
Deployment: Not verified - checked 2026-09-08 - Exact FDA submission
The reviewed sources do not establish the current exact-release hosting topology, data flow, region, tenancy, or disaster-recovery configuration.
Data hosting location: Not yet reviewed
Data retention: Not yet reviewed
Documented data use: Not yet reviewed
Hardware requirements: Not yet reviewed
Network requirements: Not yet reviewed
Identity and access: Not yet reviewed
Security: Not verified - checked 2026-09-08 - Exact FDA submission
Exact-release security controls, data retention, hosting boundaries, and scoped assurance documentation require vendor confirmation.
Installation timeline: Not yet reviewed
Training: Not verified - checked 2026-09-08 - Exact FDA submission
Current training prerequisites, competency checks, and support commitments for the exact configuration require vendor confirmation.
Monitoring: Not verified - checked 2026-09-08 - Exact FDA submission
Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.
Authorized purpose: An extension for syngo.via that assists trained physicians with automated and semi-automated analysis, visualization and reporting of cardiac CT angiography volume datasets for coronary-lesion evaluation, documentation, follow-up and treatment planning.
Authorized purpose: Canon Aquilion ONE V2.0 acquires and processes whole-body CT volumes, including head, chest, abdomen, pelvis, cardiac, extremity, inner-ear, and multi-energy examinations with the labeled reconstruction functions.
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
Accepted repository change history
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.